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Abstract
Background: There is considerable interest in identifying target genes and chromatin binding sites
for transcription factors in a genome-wide manner. Such information may become useful in
diagnosis and treatment of disease, drug target identification, and for prognostication. In cancer
diagnosis, patterns of transcription factor binding to specific regulatory chromatin elements are
expected to complement and enhance current diagnostic predictions of tumor behavior based on
protein and mRNA analyses. Signal transducer and activator of transcription-5 (Stat5) is a cytokine-
activated transcription factor implicated in growth and progression of many malignancies, including
hematopoietic, prostate, and breast cancer. We have explored immunoaffinity purification of Stat5-
bound chromatin from breast cancer cells to identify Stat5 target sites in an unbiased, genome-wide
manner.
Results: In this report, we evaluate the efficacy of a Stat5-bound chromatin library to identify valid
Stat5 chromatin binding sites within the oncogenome of T-47D human breast cancer cells. A
general problem with cloning of immunocaptured, transcription factor-bound chromatin fragments
is contamination with non-specific chromatin. However, using an optimized strategy, five out of ten
randomly selected clones could be experimentally verified to bind Stat5 both in vitro and in vivo as
tested by electrophoretic mobility shift assay and chromatin immunoprecipitation, respectively.
While there was no binding to fragments lacking a Stat5 consensus binding sequence, presence of
a Stat5 binding sequence did not assure binding.
Conclusion: A chromatin library coupled with experimental validation may productively identify
novel in vivo Stat5 chromatin binding sites in cancer, including abnormal regulatory sites in tumor-
specific neochromatin.
Background
Transcription factors function uniquely at the interface of
the genome and the proteome. A significant portion of
transcription factors serve not only as executors of gene
transcription programs, but also as biochemical sensors of
extracellular stimuli. For instance, members of the nuclear
receptor family are directly activated by lipophilic extra-
cellular ligands, and transcription factors of the Smad and
Stat families are activated by phosphorylation in response
to cytokine stimulation of cell surface receptors. Chroma-
tin-bound transcription factors that act both as sensors of
extracellular cues and as transcriptional effectors carry
exceptional instructive value about the biological state of
individual cells. Their high biological information value
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makes such factors particularly attractive for use as mark-
ers to predict disease activity and outcome, as well as pre-
dictive markers of disease-responsiveness to drugs.
Based on related and broader rationale, the second phase
of the human genome project, ENCODE (ENCyclopedia
Of DNA Elements), has been initiated with the ambitious
goal of identifying all regulatory elements of the human
genome, including chromatin binding sites for individual
transcription factors [1]. In fact, several transcription fac-
tors are prognostic biomarkers in cancer, including estro-
gen and progesterone receptors [2] and signal transducers
and activators of transcription (Stats) [3,4]. However, as a
result of tumor-specific alterations in chromatin accessi-
bility and structure, individual transcription factors may
regulate distinct gene sets in different tumor specimens.
Specifically, genes that are actively regulated vary as a
result of chromatin structure, DNA methylation, histone
modifications, and the presence of additional cofactors.
Tumor-specific patterns of transcription factor binding to
target chromatin are expected to enhance diagnostic infor-
mation beyond what is achieved through protein and
mRNA analyses. Such added diagnostic information may
directly improve disease prognostication and prediction
of tumor responsiveness to therapy.
Our laboratory is particularly interested in the role of tran-
scription factor Stat5 in human breast cancer, which is
associated with favorable prognosis, especially in early
stage malignancy [3]. Stat5 belongs to the Stat transcrip-
tion factor family, which represents latent cytoplasmic
transcription factors that are activated by phosphorylation
of a conserved tyrosine residue in response to extracellular
cytokines and hormones, such as prolactin, growth hor-
mone, erythropoietin, and several interleukins. Basal acti-
vation of Stat5 has been shown in healthy breast epithelial
cells [5] and in many early stage breast cancers, but is
gradually lost during metastatic progression [3]. Further-
more, active Stat5 correlated with higher histological dif-
ferentiation and reduced mitotic rate [6]. Additional
evidence suggests that Stat5 may actively inhibit meta-
static progression by promoting homotypic adhesion and
inhibiting tumor cell scattering [7].
Based on technical progress with immunocapture of tran-
scription factor-bound chromatin fragments, genome-
wide mapping of interaction sites may be achieved either
by hybridization of captured DNA to linear microarrays of
genomic DNA, or by cloning and sequencing of captured
chromatin fragments. Microarray-based hybridization has
been successfully used in the small yeast genome [8], but
high cost and technical hurdles remain for human
genome-wide DNA arrays at sufficient nucleotide resolu-
tion. Early efforts have focused on medium resolution
arrays of restricted portions of the genome, such as the
small chromosome 22 [9], arrays of classical promoter
regions immediately upstream of transcriptional start sites
[10], and arrays that contain CpG island clones [11]. In
contrast, generation of a genome-wide library of transcrip-
tion factor-bound chromatin fragments, a chromatin
library, represents an inclusive and unbiased approach to
the entire human genome [12]. Chromatin libraries also
hold the potential to identify transcription factor binding
to abnormal, tumor-specific neochromatin arising from
genomic instability. However, progress has been ham-
pered by a high degree of non-specific capture of irrele-
vant chromatin fragments and lack of methods for
effective validation of captured sequences.
The purpose of the work described here is to optimize
parameters to generate and validate a chromatin library
for genome-wide identification of Stat5 target chromatin
in human breast cancer. We identify novel Stat5 binding
sites from a genome-wide chromatin library and validate
the sites by prolactin-inducible Stat5 binding by electro-
phoretic mobility shift assay (EMSA) and chromatin
immunoprecipitation (ChIP).
Results and Discussion
In contrast to transcription factors that bind to chromatin
in a constitutive manner, Stat5 is a latent cytoplasmic
transcription factor that is activated by tyrosine phospho-
rylation and binds tightly to DNA in response to extracel-
lular cytokines, such as prolactin [13]. We used the well-
differentiated, estrogen receptor positive T-47D human
breast cancer cell line, which maintains robust prolactin-
induced Stat5 activation [5,14], to generate a library of
Stat5-bound chromatin fragments.
Sonication is necessary to shear genomic DNA into frag-
ments that can be easily manipulated for PCR amplifica-
tion, cloning, and sequencing. Fragments of
approximately 400 base pairs (bp) allow for a complete
sequencing read-through and are of sufficient size to
localize the fragment within the human genome with a
high degree of statistical certainty. Optimal shearing of
chromatin from formaldehyde-fixed T-47D cells into
approximately 400 bp fragments was established empiri-
cally (Figure 1A, lane 5). This target size of chromatin frag-
ments was confirmed by agarose gel electrophoresis of
two parallel sets of sonicates of cells treated with or with-
out prolactin for 30 min (Figure 1B), prior to immuno-
capture of Stat5-bound fragments. An antibody that
recognizes the highly homologous Stat5a and Stat5b iso-
forms [13] was used to capture Stat5-bound chromatin as
detailed in Methods. Before subcloning of the captured
chromatin fragments, the specificity of immunocapture
was verified by analysis of binding to known human Stat5
target chromatin. In particular, we took advantage of ear-
lier work that has identified a group of Stat5 regulatedMolecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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Specificity of immunocapture of Stat5-bound chromatin in T-47D human breast cancer cells Figure 1
Specificity of immunocapture of Stat5-bound chromatin in T-47D human breast cancer cells. A. Optimization of 
sonication parameters for shearing genomic DNA in T-47D cells. Sonication of formaldehyde-fixed cells for two 30 s pulses yielded 
~400 bp chromatin fragments. The number and time of sonication pulses are listed above each lane. B. Prolactin (PRL) pretreat-
ment did not affect chromatin fragmentation. T-47D cells were treated with (+) or without (-) 10 nM PRL for 30 min, fixed, soni-
cated (2 × 30 s), and a portion of the pre-IP samples were separated by agarose gel electrophoresis. C-E. Validation of quality of 
immunocaptured, Stat5-bound chromatin pool by ChIP analysis of known Stat5 target genes. Cells were incubated with (+) or without 
(-) 10 nM PRL for 30 min, and processed as described in Methods. Non-specific IgG was used as a negative IP control and PCR 
was performed using primers designed to specifically amplify the known Stat5 response element. PCR products shown are rep-
resentative of at least two separate amplifications of at least two independently generated pools of Stat5-chromatin complexes. 
(-) PCR ctrl indicates a negative (no template) PCR control, (+) PCR ctrl Pre-IP indicates a positive PCR control performed on 
the pre-immunoprecipitated (input) DNA, and (+) PCR ctrl Gen indicates a positive PCR control performed on purified T-47D 
genomic DNA. PRL activated Stat5 specifically associated with the promoter of CISH (C) and β-Casein (D – upper panel), but 
not α2-Macroglobulin (D – lower panel), unless cells had been pretreated for four days with glucocorticoid (E – 1 µM dexame-
thasone; Dex).Molecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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genes that have been shown to contain the Stat5 consen-
sus sequence, TTCNNNGAA, in the traditional promoter
element [13,15]. Aliquots of the captured chromatin pool
were amplified by PCR using oligonucleotide primers
flanking Stat5 binding sites within the gene promoters of
Cytokine-Inducible SH2 Protein (CISH), β-Casein, and α2-
Macroglobulin. Due to the average chromatin fragment size
of 400 bp, primers were designed to yield shorter PCR
products of 200 – 300 bp.
Stat5 was inducibly associated with the promoter of the
CISH gene response element in T-47D cells (Figure 1C).
The capture was specific, since binding was only detected
in prolactin-stimulated cells, and only when Stat5 anti-
body and not control IgG was used. PCR amplification of
intact genomic DNA is shown as a control to verify the
specificity of the PCR reaction, in addition to amplifica-
tion of the pre-immunoprecipitation chromatin fragment
pool (input DNA). Likewise, Stat5 was inducibly and spe-
cifically bound to the β-Casein gene promoter in T-47D
cells (Figure 1D, upper panel). In contrast, Stat5 did not
associate with the Stat5-response element of the α2-Mac-
roglobulin gene (Figure 1D, lower panel), a gene reportedly
responsive to Stat5 in liver [16], uterine stromal cells [17],
and ovarian cells [18,19]. However, pretreatment of T-
47D cells with the glucocorticoid hormone analog, dex-
amethasone, for four days prior to Stat5 activation made
the α2-Macroglobulin promoter accessible to Stat5 binding
(Figure 1E). It has been well established that glucocorti-
coids play a vital role in many cell types and cell processes,
including mammary differentiation. In fact, several genes
have been shown to be regulated by cooperative Stat5-glu-
cocorticoid receptor interactions [20-23]. In summary,
based on Stat5 inducibility and antibody specificity in
testing of known Stat5 chromatin interaction sites, we
concluded that the conditions for effective immunocap-
ture of Stat5-bound chromatin from T-47D cells were
established.
The enriched, Stat5-bound chromatin pool was then
cloned into a bacterial vector to generate a chromatin
library. Because sonication generates random overhangs
in double stranded DNA [24], T4 DNA polymerase was
first used to blunt-end DNA fragments. Subsequently, a
single 3' adenosine residue was added using Taq polymer-
ase, and the resulting fragments were ligated into the
pCR2.1 TA cloning vector. Transformed bacteria were
plated on ampicillin- and S-gal-containing selection
plates for blue/white screening. PCR amplification of
inserts was performed directly on white bacterial colonies
with common primers flanking the vector cloning site. A
PCR reaction under standard conditions was used to lyse
the bacteria and inactivate endogenous nucleases, cycled
36 times, and the products were separated by agarose gel
electrophoresis. Initial analysis of 389 white colonies
yielded 185 (48%) insert-containing PCR products. Figure
2 shows a display of PCR products from a run of 17
clones, in which three clones did not contain an insert and
14 clones had inserts of a median size of approximately
300 bp. PCR products containing an insert were purified
and sequenced directly without plasmid minipreps in a
cost-effective and time-saving manner. BLAST analysis
was used to localize sequences to the human genome. Of
185 inserts, 31 (17%) sequences could be unambiguously
matched to a location within the human genome.
Sequences that could not be localized were either repeti-
tive or did not produce a statistically significant homology
to the published human genome.
To validate the quality of the chromatin library, ten clones
were randomly selected and first tested for ability to bind
activated Stat5 from nuclear extracts of T-47D cells in vitro
by EMSA. Stat5 binds to the consensus sequence
TT(N5)AA and to relatively conservative variations, with
TTC(N3)GAA considered to be optimal [13,15]. Typically,
Stat5-DNA interaction by EMSA is performed on synthetic
oligonucleotides of 20–40 bp size [25]. To effectively
determine whether Stat5 interacts directly with large
immunocaptured chromatin fragments, we established
conditions for rapid validation by EMSA on chromatin
fragments up to 400 bp in length by reducing gel polyacr-
ylamide concentration to 3% and using amplification and
isotope labeling by PCR directly from the bacterial clones.
Stat5 binding in vitro was detected in seven of the ten chro-
matin fragments, as evidenced by prolactin-inducible
DNA-binding complexes that could be supershifted by a
specific anti-Stat5 antibody, but not by non-specific IgG
(Figure 3A). Negative data are only presented for one
cloned chromatin fragment (CCF #30) of the three non-
binding fragments (CCF # 21, # 25, and #30).
As a second and independent means to validate the qual-
ity of the Stat5 chromatin library, the same randomly
selected fragments were analyzed for inducible Stat5 bind-
ing in vivo using the ChIP assay. Independent pools of
immunocaptured chromatin fragments from T-47D cells
were analyzed in which Stat5 was either inactivated by
serum deprivation or activated by prolactin. Densitometry
of the PCR products was used to verify at least a 2-fold
increase in intensity between the (-) prolactin and (+) pro-
lactin samples. In all cases there was no detectable prod-
uct from the replicate samples that had been
immunoprecipitated with a non-specific IgG antibody
(data not shown), indicating a specific Stat5-mediated
capture of genomic elements. All PCR amplifications were
performed at least twice on at least two separate pools of
immunoprecipitated genomic elements.
Of the seven chromatin fragments that were positive for in
vitro Stat5 binding by EMSA, five (CCFs #5, #18, #23, #28,Molecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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and #29) were also consistently positive for in vivo Stat5
binding by ChIP assay (Figure 3B, upper panel). In addi-
tion, CCF #30 was positive by ChIP, but not by EMSA,
possibly reflecting indirect binding via other proteins.
Conversely, CCFs #11 and #14, which bound Stat5 in vitro
by EMSA, were both negative by ChIP. Corresponding
PCR products from the pre-IP DNA is shown (Figure 3B,
lower panel) and no product was detected in samples
immunoprecipitated with non-specific IgG (data not
shown). Due to sequence complexity, fragment-specific
flanking primers could not be designed for fragments CCF
#21 and #25, neither of which bound Stat5 in EMSA. The
localization data and binding validation of the ten clones
are summarized in Figure 4. Each of the CCFs that bound
Stat5 by EMSA contained at least one broad consensus
TT(N5)AA site as expected. Correspondingly, of the three
EMSA-negative CCFs, #21 and #25 lacked consensus
binding sites, while a single TT(N5)AA site was present in
CCF #30. Furthermore, the five CCFs verified to bind both
by EMSA and ChIP may be involved in transcriptional
control of nearby genes (Figure 4), or alternatively, con-
trol transcription of small regulatory RNAs [26].
Conclusions
While the present work was being completed, an inde-
pendent report also identified Stat5 binding sites using a
genome-wide approach in mouse lymphoma cells [27],
although direct binding by EMSA was not verified. We
conclude that unbiased, genome-wide strategies can now
be used to identify novel Stat5 binding sites by cloning
immunocaptured chromatin fragments. At the current
efficacy, approximately 20% of cloned Stat5-immunocap-
tured fragments from T-47D breast cancer cells could be
localized within the normal human genome, and Stat5
binding in vitro and in vivo was confirmed in approxi-
mately half of those. Further reductions in capture of non-
specific chromatin, combined with refinements in cloning
procedures [28], reduced sequencing cost, direct and
high-throughput sequencing from bacterial colonies, and
direct labeling of PCR products for EMSA testing, will
allow streamlining of the procedure for genome-wide
identification of Stat5-chromatin interaction sites. Ongo-
ing efforts are also exploring whether some of the clones
with only weak homology to the normal human genome
represent Stat5-bound neochromatin unique to the cancer
cells as a result of genomic instability.
Methods
Cell Culture and Hormones
The human breast cancer cell line T-47D was grown to
confluence in RPMI-1640 medium (Biofluids, Rockville,
MD) supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, and penicillin-streptomycin (50 IU/ml and
50 µg/ml, respectively) at 37°C with 5% CO2. Human
prolactin was kindly provided by Dr. A.F. Parlow under
the sponsorship of the NIDDKs National Hormone &
Peptide Program. Dexamethasone (Dex) was purchased
from Sigma Chemical Co. (St. Louis, MO).
Cloned Stat5-bound chromatin fragments from PRL-stimulated T-47D breast cancer cells Figure 2
Cloned Stat5-bound chromatin fragments from PRL-stimulated T-47D breast cancer cells. Immunoprecipitated 
chromatin fragments were modified for cloning into a TA cloning vector and were transformed into electrocompetent bacte-
ria. PCR was performed directly on white bacterial colonies using primers flanking the cloning site and was cycled 36 times. 
Samples were run on an agarose gel and analyzed for the presence of insert. (+) denotes vector control (no insert yields a vec-
tor-derived 172 bp product); (-) denotes negative PCR control.Molecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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Validation of cloned Stat5-bound chromatin fragments from PRL-stimulated T-47D breast cancer cells Figure 3
Validation of cloned Stat5-bound chromatin fragments from PRL-stimulated T-47D breast cancer cells. A. PRL-
activated Stat5 binds in vitro to 7 of 10 (8 shown) Cloned Chromatin Fragments (CCF) obtained from a Stat5-chromatin library as shown 
by EMSA. Nuclear extracts from confluent T-47D cells overexpressing Stat5 and incubated with (+) or without (-) 10 nM 
human PRL for 30 min were used. Prolactin-induced protein-DNA complexes are indicated by the retarded migration of probe 
in the (+) PRL lanes for each of the CCFs. Supershift reactions, or band depletions, are indicated by the antibody (Ab) added 
and signify a specific Stat5-DNA interaction when compared to the supershift control, non-specific, purified IgG. B. Validation of 
in vivo Stat5 binding to immunocaptured Cloned Chromatin Fragments (CCFs) by ChIP assay. T-47D cells were incubated with (+) or 
without (-) PRL as described and Stat5-DNA complexes were enriched by chromatin immunoprecipitation. PCR primers spe-
cific for each CCF were designed and used for amplification of two independently generated pools of Stat5-chromatin interac-
tion sites and PCR was performed twice on each pool; a representative experiment is shown. CCFs #5, #18, #23, #28, #29, 
and #30 were consistently positive for in vivo Stat5-DNA binding (upper panel). Positive PCR controls were performed on pre-
IP template (lower panel).Molecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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Chromatin Immunoprecipitation
After grown to confluence (~2 × 107 cells/T175 cm2 flask),
T-47D cells were serum starved for 24 h and then treated
with or without 10 nM hPRL for 30 min. For prodifferen-
tiation experiments with glucocorticoid pretreatment,
confluent cultures were maintained in serum-free RPMI-
1640 with 1 µM Dex dissolved in DMSO or in DMSO
alone for 96 hours, then stimulated with or without PRL
for 30 min. Proteins were then crosslinked to the chroma-
tin by the addition of formaldehyde (Fisher Scientific,
Fairlawn, NJ) to a final concentration of 1% and incu-
bated for 30 min at 37°C. The cells were rinsed, scraped,
and pelleted in ice-cold PBS with 1 mM PMSF, 2 µg/ml
aprotinin, and 2 µg/ml pepstatin A. Cell pellets were
Genomic localization of cloned Stat5-chromatin interaction sites from T-47D human breast cancer cells Figure 4
Genomic localization of cloned Stat5-chromatin interaction sites from T-47D human breast cancer cells. A 
karyogram of the human genome illustrates the loci of the cloned Stat5 binding sites. Each site is designated by the CCF 
number and is localized to its specific area of the genome, based on BLAST alignment. CCFs positive by EMSA are labeled "E", 
and CCFs positive by ChIP are labeled "C". The genomic localization and two nearest genes of each verified CCF is given by 
the genomic position of the centrally located nucleotide: CCF#5: 8q12.1:58980112 (LOC389663-similar to hypothetical pro-
tein; MGC39325-hypothetical protein); CCF#18: 3q29:193835263 (FGF12-fibroblast growth factor 12; LOC151963-similar to 
BcDNA:GH11415 gene product); CCF#23: 5q33.1:147357743 (LOC391839-similar to elongation factor 1 gamma; SPINK5-ser-
ine protease inhibitor, Kazal type, 5); CCF#28: 6q24.1:142177080 (LOC340149-hypothetical protein; NMBR-neuromedin B 
receptor); CCF#29: 6q13:74774694 (CD109 antigen); SLC17A5-solute carrier family 17 (anion/sugar transporter) member 5). 
Other CCFs include: CCF#11: 7q31.1:111547940; CCF#14: 15q11.2:21265800; CCF#21: 18q21.2:49639649; CCF#25: 
Xq28:153691722; CCF#30: 1p34.1:43842775.
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resuspended in 400 µl lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl, pH 8.0, 1 mM PMSF, 2 µg/ml
aprotinin, and 2 µg/ml pepstatin A) and the lysates were
sonicated using a Sonic Dismembrator (Fisher Scientific,
Pittsburgh, PA), fitted with a tapered microtip set to an
amplitude of 50% and were pulsed twice for 30 s. Debris
was pelleted by centrifugation for 10 min at 13,200 RPM
at 4°C. The supernatants were then diluted 10-fold in IP
buffer (0.1% SDS, 1.1% Triton-X, 1.2 mM EDTA, 16.7
mM Tris-HCl, pH 8.1, 16.7 mM NaCl, 1 mM PMSF, 2 µg/
ml aprotinin, and 2 µg/ml pepstatin A) and 1% was set
aside for Pre-IP or input sample. The solution was then
pre-cleared with beads (50% protein A-sepharose, 1 mg/
ml poly dI-dC, 0.1% BSA, in TE, pH 7.4) for 30 min at
4°C. Next, the samples were incubated overnight with
Stat5 antibody (N-20, Santa Cruz Biotechnology) or IgG
IP-control followed by immunoprecipitation with pre-
incubated beads. The samples (beads) were then washed
once with each of these buffers in the following order:
Wash Buffer 1 (0.1% SDS, 1% Triton-X, 2 mM EDTA, 20
mM Tris-HCl, pH 8.0, 150 mM NaCl), Wash Buffer 2
(0.1% SDS, 1% Triton-X, 2 mM EDTA, 20 mM Tris-HCl,
pH 8.0, 500 mM NaCl), Wash Buffer 3 (0.25 M LiCl, 1%
NP-40, 1% Na-deoxycholate, 10 mM Tris-HCl, pH 8.0, 1
mM EDTA), then twice with Wash Buffer 4 (TE, pH 8.0).
The samples were eluted from the beads in 1% SDS and
0.1 M NaHCO3. Next, the cross-links were reversed with
0.2 M NaCl overnight at 65°C followed by protein diges-
tion with proteinase K for 1 hour at 45°C. The DNA was
recovered by phenol:chloroform extraction and ethanol
precipitation. This pool was then used as PCR template or
could be blunted with T4 DNA polymerase (New England
Biolabs, Beverly, MA) at 37°C for 5 minutes under stand-
ard conditions for uniform cloning. Taq DNA polymerase
(New England Biolabs) was then used to add a 3' A over-
hang for cloning into a TOPO TA cloning kit (Invitrogen,
Carlsbad, CA). The ligated vectors were transformed into
electrocompetent bacteria, DH-5αE (Invitrogen), using
the manufacturer's recommendations for transformation
in a Bio-Rad Gene-Pulser (Hercules, CA), and plated on S-
Gal/Ampicillin plates (Sigma Chemical Co., St. Louis,
MO). Positive clones by blue-white screening were then
analyzed directly by colony PCR in a standard reaction
with vector-specific M13 and T7 primers that flank the
cloning site and were incubated at 94°C for 4 min and
cycled at 94°C for 30 s, 55°C for 45 s, and 72°C for 30 s.
Colonies with quantifiable inserts were then purified
(QiaQuick PCR purification kit, Qiagen, Valencia, CA),
sequenced, and localized using BLAST (NCBI, NIH,
Bethesda, MD).
Validation using known Stat5 responsive genes
The following primers were designed to flank the Stat5
binding site in the promoter of the following genes: α2-
Macroglobulin forward 5' TTT AGC CCT CCA GGG ATT CT
3', reverse 5' CAA TCC ATC TGG TCC CAA AC 3'; β-Casein
forward 5' GGA GAA ACA GTT TGC CTC ACA 3', reverse
5' CCT AGT GGG GCC TTG AGA TT 3'; CISH forward 5'
CTA TTG GCC CTC CCC GAC 3', reverse 5' AGC TGC TGC
CTA ATC CTT TG 3'. PCR amplifications shown are repre-
sentative of at least 2 separate amplifications of at least 2
independently generated immunocaptured pools of
Stat5-chromatin complexes.
Preparation of cellular extracts for EMSA
After reaching confluence, T-47D cells were infected with
adenovirus containing wild type Stat5 at a Multiciplity Of
Infection (MOI) = 6.67, as described previously [29]. Par-
allel samples of T-47D cells were not exposed to adenovi-
rus as a mock infection (standard control). After infection,
the cells were cultured in serum-free medium for 24
hours, then stimulated for 30 min with 10 nM hPRL, the
culture medium was removed, and the cells were collected
as described above. Nuclear lysates were collected as
described previously [5,25].
Generation of radiolabeled DNA probes
Radiolabeled products were generated by PCR in a 10 µl
reaction under standard conditions with the addition of
0.25 µl α32P dATP (10 mCi/ml; Amersham-Pharmacia,
Piscataway, NJ). Initially the samples were incubated at
94°C for 1 min, then cycled 36 times at 94°C for 30 s,
55°C for 30 s, and 72°C for 30 s. The reaction was then
held at 72°C for 5 min following the cycling to allow for
product fill-in and addition of a 3' terminal "A". After
completion of the cycling, the PCR products were purified
using the Qiagen PCR purification kit, according to man-
ufacturer's instructions. The final products were eluted in
50 µl and stored at -20°C until use.
DNA-protein binding reaction
The DNA-protein binding reactions were performed in a
10 µl mixture containing 3 µl of nuclear extract from the
respective sample, and 1 µg of double-stranded poly dI:dC
(Boehringer Mannheim, Indianapolis, IN), as previously
described [25]. After 1 h on ice, samples (with 1 ng
specific anti-Stat5 antibody (Santa Cruz Biotechnology),
or 1 ng non-specific, purified IgG (Sigma), or no anti-
body) were incubated with 2.0 µl 32P-labeled PCR probe
and incubated for 20 min at room temperature. The sam-
ples were then resolved in a 3% non-denaturing polyacry-
lamide gel, as previously described [25].
ChIP in vivo validation
As an independent validation technique, we designed
primers specific to each cloned chromatin fragment (CCF)
then performed PCR on a separately-generated enriched
pool of immunoprecipitated Stat5-chromatin interaction
sites. The following primers were used for PCR: CCF #5
forward 5' TGA CAT CAG TGA GAG TGG AGG 3', reverseMolecular Cancer 2005, 4:6 http://www.molecular-cancer.com/content/4/1/6
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5' TGA GGC TGT AAT GTC ACT CAG AA 3'; CCF #11 for-
ward 5' GGA CAC ATC CAC TAC TGC CA, reverse 5' AAA
AGA AGT GCA GTT CAG GAT AA 3'; CCF #14 forward 5'
GCC TGT GTG ATA TCA TAT GGA AAG 3', reverse 5' TTT
CCA AGA ACT TAT CAG AAT GAC TT 3'; CCF #18 forward
5' TCA GTC TTC CTC TTT CCC CA 3', reverse 5' CGG CTT
ACA TTC TGT GTC GC 3'; CCF #23 forward 5' CAT ATC
TGT CTA CAA ATA ACA GTT CCC 3', reverse 5' AAT AGA
GGG CAG AGT TAA GAA TCA AA 3'; CCF #28 forward 5'
AAG CCT GAA AAG AAA AAT CTC A 3', reverse 5' CCT
GAC ACA TCC AGA CTT GG 3'; CCF #29 forward 5' CAG
ACG TTT GCT GGA AGA TAT G 3', reverse 5' TTG TTC CAT
GAA ACC AGG G 3'; CCF #30 forward 5' AAG GCC ATT
GAA GTG AGG TG 3', reverse 5' CCA TCA GCC AGT CAT
TGA AG 3'. The PCR was performed with standard condi-
tions using template immunoprecipitated from cells
treated with or without prolactin to indicate Stat5
inducibility and was executed at least twice on each of 2
separate pools.
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